<DOC>
	<DOCNO>NCT00017212</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness exatecan mesylate treat patient metastatic stomach cancer .</brief_summary>
	<brief_title>DX-8951f Treating Patients With Metastatic Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate patient previously untreated metastatic gastric cancer treat exatecan mesylate ( DX-8951f ) . - Determine time tumor progression patient population treat drug . - Determine survival 6 12 month patient population treat drug . - Determine quantitative qualitative toxic effect drug patient population . - Determine pharmacokinetics drug plasma patient . OUTLINE : This multicenter study . Patients receive exatecan mesylate ( DX-8951f ) IV 30 minute day 1-5 . Treatment repeat every 21 day least 2 course absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Exatecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm gastric gastroesophageal adenocarcinoma Lymph node involvement and/or distant metastasis No squamous cell carcinoma , small cell carcinoma , lymphoma , leiomyosarcoma stomach Measurable disease indicator lesion outside field prior radiotherapy At least 20 mm conventional scan OR At least 10 mm spiral CT scan Nonmeasurable lesion include follow : Primary tumor Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonitis Cystic lesion Abdominal mass confirm followed imaging technique No prior treatment locally advance metastatic disease Prior adjuvant treatment allow disease recurrence note least 6 month completion adjuvant treatment No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 2.0 mg/dL AST ALT great 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Albumin least 2.8 g/dL PT INR great 1.5 time ULN ( coumadin independent ) Renal : Creatinine great 1.5 mg/dL Cardiovascular : No active congestive heart failure No uncontrolled angina No myocardial infarction within past 6 month Other : No concurrent serious infection No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No overt psychosis , mental disability , incompetence would preclude informed consent No lifethreatening illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics Biologic therapy : No concurrent anticancer biologic therapy No concurrent prophylactic colony stimulate factor first course therapy Chemotherapy : Recovered prior adjuvant chemotherapy No concurrent anticancer chemotherapy No concurrent anticancer cytotoxic therapy Endocrine therapy : Concurrent megestrol appetite stimulation allow Radiotherapy : At least 4 week since prior radiotherapy recover No prior widefield radiotherapy 25 % bone marrow No concurrent anticancer radiotherapy Surgery : At least 4 week since prior major surgery recover No concurrent anticancer surgery Other : No investigational drug ( include analgesic antiemetic ) least 4 week prior , , 4 week study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>